EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
← catalyst calendarNCT05284747 · readout in 283 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →. With Colorado Prevention Center.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
6,019actual
Sites
120
Countries
Brazil, Sweden, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-26 | actual | When the study began enrolling |
| Primary completion | 2027-05-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-29 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiovascular Disease
- Myocardial Infarction
- Stroke
- Coronary Revascularization
Interventions
- Drug: Evolocumab — also filed as Repatha, AMG 145
- Drug: Routine Lipid Management
Primary outcome
what the primary-completion date above is the date OFTotal (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death
measured From Baseline to End of Study (Approximately 3.5 Years)
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed